Home » Stocks » LPTX

Leap Therapeutics, Inc. (LPTX)

Stock Price: $1.98 USD -0.10 (-4.81%)
Updated Oct 28, 2020 2:00 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 118.12M
Revenue (ttm) 750,000
Net Income (ttm) -29.68M
Shares Out 59.66M
EPS (ttm) -1.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $1.98
Previous Close $2.08
Change ($) -0.10
Change (%) -4.81%
Day's Open 2.02
Day's Range 1.93 - 2.04
Day's Volume 262,188
52-Week Range 0.57 - 3.18

More Stats

Market Cap 118.12M
Enterprise Value 52.65M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 59.66M
Float 46.59M
EPS (basic) -1.32
EPS (diluted) -1.21
FCF / Share -0.50
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 821,824
Short Ratio 1.45
Short % of Float 1.76%
Beta 1.60
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 157.50
PB Ratio 2.11
Revenue 750,000
Operating Income -30.07M
Net Income -29.68M
Free Cash Flow -26.21M
Net Cash 65.47M
Net Cash / Share 1.10
Gross Margin 100.00%
Operating Margin -4,009.60%
Profit Margin -5,300.30%
FCF Margin -3,495.07%
ROA -42.65%
ROE -83.99%
ROIC 597.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 3
Overweight 2
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$5.10*
(157.58% upside)
Low
2.50
Current: $1.98
High
8.00
Target: 5.10
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue-------
Operating Income-33.45-30.75-32.35-27.30-11.92-20.92-13.87
Net Income-32.90-23.14-29.73-25.63-12.05-25.45-18.32
Shares Outstanding22.5814.149.169.399.39--
Earnings Per Share-1.47-2.11-3.31--1.16-2.15-2.46
Operating Cash Flow-26.90-26.03-22.14-25.34-8.10-18.02-9.94
Capital Expenditures-0.09--0.06-0.14--0.23-0.12
Free Cash Flow-26.99-26.03-22.20-25.48-8.10-18.24-10.06
Cash & Equivalents4.9917.6625.740.790.4146.18-
Total Debt0.55--30.273.14--
Net Cash / Debt4.4417.6625.74-29.48-2.7446.18-
Assets7.4519.0729.066.461.2648.70-
Liabilities9.209.9017.9536.1671.552.49-
Book Value-1.759.1811.12-100-70.2946.21-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Leap Therapeutics, Inc.
Country United States
Employees 24
CEO Doug E. Onsi

Stock Information

Ticker Symbol LPTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: LPTX

Description

Leap Therapeutics, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company's clinical stage programs also include TRX518, a monoclonal antibody, which is in clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.